These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38538206)

  • 41. First clinical experiences with inclisiran in a real-world setting.
    Mulder JWCM; Galema-Boers AMH; Roeters van Lennep JE
    J Clin Lipidol; 2023; 17(6):818-827. PubMed ID: 37775462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
    Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inclisiran and cardiovascular events: a comprehensive review of efficacy, safety, and future perspectives.
    Mohamed AA; Ray KK
    Curr Opin Cardiol; 2023 Nov; 38(6):527-532. PubMed ID: 37522763
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
    Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS;
    Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Inclisiran.
    Asbeutah AAA; Asbeutah SA; Abu-Assi MA
    Am J Cardiol; 2020 Aug; 128():218-219. PubMed ID: 32482309
    [No Abstract]   [Full Text] [Related]  

  • 47. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
    Scheen AJ; Wallemacq C; Lancellotti P
    Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials.
    Cupido AJ; Kastelein JJP
    Cardiovasc Res; 2020 Sep; 116(11):e136-e139. PubMed ID: 32766688
    [No Abstract]   [Full Text] [Related]  

  • 49. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials.
    Landmesser U; Koenig W; Leiter LA; Raal FJ; Ray KK; Wright RS; Han J; Conde LG; Schwartz GG
    Atherosclerosis; 2023 Dec; 386():117354. PubMed ID: 38016401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Bempedoic acid and inclisiran : two new drugs to treat hypercholesterolemia].
    Wallemacq CM; De Flines JC; Mathieu FD
    Rev Med Suisse; 2021 Aug; 17(747):1411-1417. PubMed ID: 34431634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
    Lloyd-Jones DM
    JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
    [No Abstract]   [Full Text] [Related]  

  • 52. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
    Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A
    Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9.
    German CA; Shapiro MD
    BioDrugs; 2020 Feb; 34(1):1-9. PubMed ID: 31782112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
    Ascaso JF
    Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861
    [No Abstract]   [Full Text] [Related]  

  • 56. Novel therapies for familial hypercholesterolemia.
    Mohamed F; Seedat F; Raal FJ
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
    Mahmood T; Shapiro MD
    Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inclisiran: First Approval.
    Lamb YN
    Drugs; 2021 Feb; 81(3):389-395. PubMed ID: 33620677
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PCSK9 inhibition for autosomal recessive hypercholesterolemia.
    Chemello K; Martín C; Lambert G
    Atherosclerosis; 2019 May; 284():209-211. PubMed ID: 30862376
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.